Bergmann I E, Malirat V, Neitzert E
Pan American Foot-and-Mouth Disease Center (PANAFTOSA), PAHO/WHO, PO Box 589, CEP:20010-974 Rio de Janeiro, RJ, Brazil.
Biologicals. 2005 Dec;33(4):235-9. doi: 10.1016/j.biologicals.2005.08.013. Epub 2005 Oct 28.
The ability of foot-and-mouth disease virus (FMDV) to establish subclinical and even persistent infection, the so called carrier state, imposes the need to reliably demonstrate absence of viral circulation, to monitor the progress of control measures, either during eradication programs or after reintroduction of virus in free areas. This demonstration becomes critical in immunized populations, because of the concern that silent viral circulation could be hidden by immunization. This concern originates from the fact that vaccination against foot-and-mouth disease (FMD) protects against clinical disease, but not necessarily against subclinical infection or establishment of the carrier state in cattle. A novel approach, developed and validated at PANAFTOSA during the 1990s, based on an immunoenzymatic system for detection of antibodies against non-capsid proteins (NCP) has proven valuable for monitoring viral circulation within and between herds, irrespective of the vaccination status. Antibodies against NCP are induced during infection but, in principle, not upon vaccination. The validation of this system led to its international recognition as the OIE index test. The fitness of this serosurvey tool to assess viral circulation in systematically vaccinated populations was demonstrated through its extensive application in most regions in South America. The experience attained in these regions supported the incorporation of the "free of FMD with vaccination" provisions into the OIE code. Likewise, it opened the way to alternatives to the "stamping out" policy. The results gave input to an old controversy related to the real epidemiological significance, if any, of carrier animals under the vaccination conditions in South America, and supported the development of recommendations and guidelines that are being implemented for serosurveys that go with control measures in vaccinated populations.
口蹄疫病毒(FMDV)具有引发亚临床甚至持续性感染(即所谓的携带状态)的能力,这就需要可靠地证明病毒没有传播,以便在根除计划期间或在无病地区重新引入病毒后监测控制措施的进展情况。在免疫群体中,这种证明变得至关重要,因为人们担心免疫接种可能掩盖病毒的隐性传播。这种担忧源于以下事实:口蹄疫(FMD)疫苗接种可预防临床疾病,但不一定能预防亚临床感染或牛群中携带状态的形成。20世纪90年代,PANAFTOSA研发并验证了一种基于免疫酶系统检测非衣壳蛋白(NCP)抗体的新方法,该方法已被证明对于监测畜群内部和之间的病毒传播非常有价值,无论其疫苗接种状态如何。感染期间会诱导产生针对NCP的抗体,但原则上接种疫苗不会诱导产生。该系统的验证使其在国际上被认可为世界动物卫生组织(OIE)的标准检测方法。通过在南美洲大部分地区的广泛应用,证明了这种血清学调查工具适用于评估系统接种疫苗群体中的病毒传播情况。在这些地区获得的经验支持将“接种疫苗无口蹄疫”条款纳入OIE法典。同样,它为替代“扑杀”政策开辟了道路。这些结果为一个长期存在的争议提供了依据,即在南美洲的疫苗接种条件下,携带病毒动物的实际流行病学意义(如果有的话),并支持制定与接种疫苗群体的控制措施相关的血清学调查建议和指南。